Diverse inflammatory diseases, infections and malignancies are associated with wasting
syndromes. In many of these conditions, the standards for diagnosis and treatment are …

Cachexia, a systemic wasting condition, is considered a late consequence of diseases,
including cancer, organ failure, or infections, and contributes to significant morbidity and …

Most patients with advanced solid cancers exhibit features of cachexia, a debilitating
syndrome characterized by progressive loss of skeletal muscle mass and strength. Because …

Cancer cachexia is a systemic hypoanabolic and catabolic syndrome that diminishes the
quality of life of cancer patients, decreases the efficiency of therapeutic strategies and …

Cachexia is associated with decreased survival in cancer patients and has a prevalence of
up to 80%. The etiology of cachexia is poorly understood, and limited treatment options …

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive type of cancer with
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …

Skeletal muscle atrophy is a debilitating condition that occurs with aging and disease, but
the underlying mechanisms are incompletely understood. Previous work determined that …

Background Cancer‐related muscle wasting occurs in most cancer patients. An important
regulator of adult muscle mass and function is the Akt–mTORC1 pathway. While Akt …

Cancer cachexia is a complex multi‐organ catabolic syndrome that reduces mobility,
increases fatigue, decreases the efficiency of therapeutic strategies, diminishes the quality of …

Pancreatic cancer is one of the leading determinants of global cancer mortality, and its
incidence is predicted to increase, to become in 2030 the second most common cause of …